Rx Biosciences has successfully completed eight years of providing quality services and products to the international scientific community. During the last eight years, we have collaborated with renowned research organizations, pharmaceutical companies and academic institutes on long term projects assisting them to achieve their milestones. We have constantly been trying to enhance our scope of services and products by emphasizing upon R&D, in order to improve the existing technologies and incorporate new discoveries to its portfolio.
- Rx Biosciences has established itself as the number one source for-
- cDNA library construction coupled with high throughput sequencing
- BAC library construction-Random SHEARING as well as RESTRICTION ENZYME protocols
- High throughput platform for DNA isolation from BAC clone
- High throughput BAC end sequencing
- Next Generation 454 Sequencing
Rx Biosciences was awarded SBIR grant for the detection of protein kinase substrates involved in the onset and progression of prostate cancer and leukemia. National Cancer Institute (NCI) sponsored grant will develop a facile technology (SIMPKIN) for the identification of protein kinase substrates. The novel technology platform holds the promise of detection of protein phosphorylation in real-time.
